UK laboratory research reference on tesamorelin: stabilised GHRH analogue, approved indication in HIV lipodystrophy, visceral fat reduction data, MASLD research, pharmacokinetics and protocol design. 2026 research-grade reference.
UK laboratory research reference on MK-677 (ibutamoren): oral ghrelin-receptor agonism, pharmacokinetics, IGF-1 dose-response, long-term safety data, and study protocol design. Research-grade reference, 2026.
UK laboratory research reference on CJC-1295 (with or without DAC) and ipamorelin: receptor pharmacology, combined-stack rationale, dose-response data, reconstitution and protocol design. 2026 research-grade reference.
UK laboratory research reference on GLP-1 receptor agonists in MASLD and MASH: SYNERGY-NASH tirzepatide data, ESSENCE semaglutide data, retatrutide hepatic results, MRI-PDFF and histology endpoints, protocol design. 2026.
Comprehensive UK laboratory research reference on GLP-1 receptor agonist side effects: mechanism of GI adverse events, class-level signals, pancreatitis, gallbladder and thyroid signals, and research-protocol mitigation strategies. 2026 update.
Head-to-head laboratory research reference comparing tirzepatide (GLP-1/GIP dual agonist) to semaglutide (GLP-1 mono-agonist): SURMOUNT-5 data, receptor pharmacology, cardiometabolic endpoints and protocol design. UK research-grade, 2026.
Head-to-head laboratory research reference comparing liraglutide and semaglutide: STEP-8 and SUSTAIN-10 data, receptor pharmacology, half-life, dosing cadence and study protocol considerations. UK research-grade reference, 2026.
A 2026 UK research reference for semaglutide — the GLP-1 receptor agonist behind STEP (obesity), SUSTAIN (T2DM), SELECT (cardiovascular outcomes), and FLOW (diabetic kidney disease). Mechanism, clinical evidence summary, protocol design, and UK procurement considerations for laboratory research.
A 2026 UK research reference to TB-500 dosing and reconstitution — the published rodent dose range, reconstitution with bacteriostatic water, weekly vs twice-weekly schedules, storage, and protocol design considerations for UK laboratory research in tissue repair, cardiac and musculoskeletal studies.
A 2026 UK research review of TB-500 and thymosin beta-4 in cardiac research — the landmark Nature studies on post-MI research applications, epicardial progenitor mobilisation, cardiomyocyte survival, and the translational cardiac work that makes TB-500 the distinctive cardiac-research peptide in its class.
A 2026 UK research review of TB-500 in skeletal muscle and connective tissue repair — the rodent injury model evidence, mechanistic basis in actin cytoskeleton regulation, dose and protocol conventions, and comparison to BPC-157 in muscle-specific endpoints.
A 2026 UK research review of TB-500 and its parent molecule thymosin beta-4 (TB-4) — the G-actin sequestration mechanism, cell migration regulation, preclinical evidence across cardiac, dermal, corneal and neural tissue repair, and protocol design for UK laboratory research.
